Parexel and Japanese Foundation for Cancer Research (JFCR) Form Strategic Alliance to Fast-Track Oncology Clinical Trials in Japan

Parexel, a leading global clinical research organization, and the Japanese Foundation for Cancer Research (JFCR) have unveiled a strategic alliance aimed at accelerating access to oncology clinical trials in Japan.

Under this collaboration, JFCR will become a part of Parexel’s Global Site Alliance network for oncology clinical trials, offering increased opportunities for Japanese patients to participate in cutting-edge cancer research. Parexel will leverage JFCR’s expertise to assist sponsors in developing protocols aligned with Japan's standard of care and regulatory approval processes. This collaborative effort is expected to streamline patient recruitment and study start-up processes.

Shigehiro Miki, Parexel Corporate Vice President, and General Manager of Japan, expressed optimism about the alliance, stating, "Consistent with global trends, the incidence of cancer is expected to increase in Japan. We look forward to JFCR joining Parexel’s Site Alliance Network and working together to eliminate barriers and increase access to potentially life-changing treatments for Japanese patients."

Dr. Takeshi Sano, Hospital Director at the Cancer Institute Hospital, JFCR, emphasized the shared urgency to enable sponsors to conduct trials in Japan and ensure patient access to innovative clinical research. He stated, "To improve the well-being of people worldwide by conquering cancer is the fundamental principle of JFCR. We look forward to collaborating closely with Parexel to realize our principle."

This strategic alliance signifies a joint commitment to overcoming barriers and expediting the development of transformative cancer treatments, ultimately benefiting patients not only in Japan but worldwide.